# Efficacy and Safety of Angong Niuhuang Wan for Stroke

Study · id `cardio:ct-nct04236427` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04236427](<https://clinicaltrials.gov/study/NCT04236427>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04236427

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04236427. Randomized; quadruple masking; primary purpose prevention. Start 2019-10-15 (actual); primary completion 2022-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04236427, source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)
- Started: 2019-10-15 (actual) (ClinicalTrials.gov record NCT04236427, source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)
- Primary completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04236427, source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)
- Completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT04236427, source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT04236427, source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04236427-2021-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Angong Niuhuang Wan for Stroke
- Condition: Stroke (CVA) or TIA
- Intervention (Drug): Angong Niuhuang Wan
- Intervention (Drug): Angong Niuhuang Wan Placebo
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)

## Provenance

Content hash: 67fd884b0734d286fcf8e64ff510ffed430255417d171ceedc8d7c33b5051257
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
